Literature DB >> 31385949

Quality of survival and cognitive performance in children treated for medulloblastoma in the PNET 4 randomized controlled trial.

Hugo Câmara-Costa1, Kim S Bull2, Colin Kennedy2, Andreas Wiener3, Gabriele Calaminus3, Anika Resch4, Virginie Kieffer5, Clémence Lalande6, Geraldina Poggi7, Katja von Hoff4, Jacques Grill6,8, François Doz9, Stefan Rutkowski4, Maura Massimino10, Rolf-Dieter Kortmann11, Birgitta Lannering12, Georges Dellatolas1, Mathilde Chevignard13.   

Abstract

BACKGROUND: The relationship between direct assessments of cognitive performance and questionnaires assessing quality of survival (QoS) is reported to be weak-to-nonexistent. Conversely, the associations between questionnaires evaluating distinct domains of QoS tend to be strong. This pattern remains understudied.
METHODS: In the HIT-SIOP PNET4 randomized controlled trial, cognitive assessments, including Full Scale, Verbal and Performance IQ, Working Memory, and Processing Speed, were undertaken in 137 survivors of standard-risk medulloblastoma from 4 European countries. QoS questionnaires, including self-reports and/or parent reports of the Behavior Rating Inventory of Executive Function (BRIEF), the Health Utilities Index, the Strengths and Difficulties Questionnaire, and the Pediatric Quality of Life Inventory, were completed for 151 survivors. Correlations among direct cognitive assessments, QoS questionnaires, and clinical data were examined in participants with both assessments available (n = 86).
RESULTS: Correlations between direct measures of cognitive performance and QoS questionnaires were weak, except for moderate correlations between the BRIEF Metacognition Index (parent report) and working memory (r = .32) and between health status (self-report) and cognitive outcomes (r = .35-.44). Correlations among QoS questionnaires were moderate to strong both for parent and self-report (r = .39-.76). Principal Component Analysis demonstrated that questionnaires and cognitive assessments loaded on 2 separate factors.
CONCLUSIONS: We hypothesize that the strong correlations among QoS questionnaires is partially attributable to the positive/negative polarity of all questions on the questionnaires, coupled with the relative absence of disease-specific questions. These factors may be influenced by respondents' personality and emotional characteristics, unlike direct assessments of cognitive functioning, and should be taken into account in clinical trials.

Entities:  

Keywords:  everyday executive functioning; intellectual ability; medulloblastoma; outcome; quality of survival

Year:  2017        PMID: 31385949      PMCID: PMC6655414          DOI: 10.1093/nop/npw028

Source DB:  PubMed          Journal:  Neurooncol Pract        ISSN: 2054-2577


  52 in total

1.  Integrating response shift into health-related quality of life research: a theoretical model.

Authors:  M A Sprangers; C E Schwartz
Journal:  Soc Sci Med       Date:  1999-06       Impact factor: 4.634

2.  Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma.

Authors:  Raymond K Mulhern; Shawna L Palmer; Thomas E Merchant; Dana Wallace; Mehmet Kocak; Pim Brouwers; Kevin Krull; Murali Chintagumpala; Robyn Stargatt; David M Ashley; Vida L Tyc; Larry Kun; James Boyett; Amar Gajjar
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

3.  Profile of daily life in children with brain tumors: an assessment of health-related quality of life.

Authors:  Sundeep R Bhat; Tress L Goodwin; Tasha M Burwinkle; Meagan F Lansdale; Gary V Dahl; Stephen L Huhn; Iris C Gibbs; Sarah S Donaldson; Ruth K Rosenblum; James W Varni; Paul G Fisher
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

4.  Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis.

Authors:  S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  Neuropsychological performance and quality of life of 10 year survivors of childhood medulloblastoma.

Authors:  Ann M Maddrey; Jon A Bergeron; Elizabeth R Lombardo; Noelle K McDonald; Arlynn F Mulne; Paul D Barenberg; Daniel C Bowers
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

6.  Standardized quantitative assessment of brain tumor survivors treated within clinical trials in childhood.

Authors:  A Glaser; C Kennedy; J Punt; D Walker
Journal:  Int J Cancer Suppl       Date:  1999

7.  Cross-cultural adaptation of a health status classification system in children with cancer. First results of the French adaptation of the Health Utilities Index Marks 2 and 3.

Authors:  C Le Galès; N Costet; J C Gentet; C Kalifa; D Frappaz; C Edan; E Sariban; D Plantaz; F Doz
Journal:  Int J Cancer Suppl       Date:  1999

8.  The PedsQL: measurement model for the pediatric quality of life inventory.

Authors:  J W Varni; M Seid; C A Rode
Journal:  Med Care       Date:  1999-02       Impact factor: 2.983

9.  A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer.

Authors:  D Feeny; W Furlong; R D Barr; G W Torrance; P Rosenbaum; S Weitzman
Journal:  J Clin Oncol       Date:  1992-06       Impact factor: 44.544

10.  The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity.

Authors:  James W Varni; Tasha M Burwinkle; Michael Seid; Douglas Skarr
Journal:  Ambul Pediatr       Date:  2003 Nov-Dec
View more
  3 in total

1.  Neurocognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: Long-term mature outcomes of a prospective study.

Authors:  Tejpal Gupta; Babusha Kalra; Savita Goswami; Jayita Deodhar; Pallavi Rane; Sridhar Epari; Aliasgar Moiyadi; Archya Dasgupta; Abhishek Chatterjee; Girish Chinnaswamy
Journal:  Neurooncol Pract       Date:  2022-03-13

2.  Self- and parent-reported Quality of Life 7 years after severe childhood traumatic brain injury in the Traumatisme Grave de l'Enfant cohort: associations with objective and subjective factors and outcomes.

Authors:  Hugo Câmara-Costa; Marion Opatowski; Leila Francillette; Hanna Toure; Dominique Brugel; Anne Laurent-Vannier; Philippe Meyer; Laurence Watier; Georges Dellatolas; Mathilde Chevignard
Journal:  Qual Life Res       Date:  2019-09-23       Impact factor: 4.147

Review 3.  Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial.

Authors:  Simon Bailey; Nicolas André; Lorenza Gandola; Maura Massimino; Stefan Rutkowski; Steven C Clifford
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.